Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861254 | 0.88 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19199734 | 0.86 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13799649 | 0.84 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL28329410 | 0.84 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL4434497 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL10046336 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2429327 | 0.84 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1328433 | 0.84 | CTSD (0.54) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL30859928 | 0.83 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL23775760 | 0.79 | SIGMAR1 (0.63) | SIGMAR1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | SIGMAR1 2159/4885ALDH1A1 163/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.